contents

What’s going on at the Foundation
We are on a mission!
A new health challenge partnership
The 2022 Discovery Award Cohort
Select Discovery Award research highlights
Thankful and flourishing
2022 Discovery Award Grant Panel reviewers
A special thank you
The Banting Research Foundation at 100

3
5
7
8
12
21
22
24
25
What’s going on at the Foundation

Advocating for early career researchers in Canada

Our highly competitive Discovery Award Program, established in 1925, empowers early career scientists and supports them to explore bold, new ideas.

Eligible investigators are in the first three years of their faculty appointment and demonstrate:

• Innovation potential
• Scientific excellence, and
• Financial need

The Discovery Award gives new scientists a big boost at a very important time in their careers.

88% of our Awardees successfully obtain further competitive grant funding from federal granting agencies, within the first five years of receiving a Discovery Award!

Many recipients have gone on to make outstanding discoveries that have aided the understanding, diagnosis, and treatment of challenging health conditions.

“As a new principal investigator, obtaining the first grant is one of the most difficult things. Once this is achieved, one does not have to convince reviewers anymore.”

Dr. Marc Pouliot, 2000 Discovery Awardee
Axis Director, Infectious and Immune Diseases Centre Hospitalier de l’Université Laval

“When you’re a young investigator and you don’t have a lot of funding, it’s hard to move to the next level…”

Dr. Janet Rossant, 1983 Discovery Awardee
President & Scientific Director Gairdner Foundation
Recipients have emerged as Canada’s leaders and luminaries in medical sciences including 32 Discovery Awardees to date who have been inducted into the Order of Canada.

**William T. Mustard**
OC, MBE
1950 Discovery Awardee
Created the ‘Mustard Procedure’ that is still used worldwide. The surgery corrects a complex heart defect in ‘blue babies’.

**Louis Siminovitch**
CC, OOnt, FRS, FRSC
1958 Discovery Awardee
The Canadian founding father of human genetics research.

**Mladen Vranic**
OC, OOnt, MD, DSc
1966 Discovery Awardee
Best known for his work on exercise and stress in diabetes, and the prevention of hypoglycemia.

**John A. Dirks**
CM, FRSC, FRCPC
1967 Discovery Awardee
Famous for transforming the Gairdner Foundation International Awards into ‘Canada’s Nobel Prizes’.

**Henry G. Friesen**
CC, OM, FRSC
1972 Discovery Awardee
Research on human growth hormone made possible successful replacement therapy in hormone-deficient children. Conceptualized and founded the Canadian Institutes of Health Research.

**Adolfo José de Bold**
OC, FRSC
1980 Discovery Awardee
Discovered a new hormone that plays a role in regulating blood pressure, blood volume, and cardiovascular growth, and proving the endocrine function of the heart.

**Brenda L. Gallie**
CM, OOnt, MD, FRCSC
1983 Discovery Awardee
Discovered the genetic mutations that cause retinoblastoma — an eye cancer that commonly affects young children. She created DEPICT HEALTH.
We are on a mission!

Climate change is the biggest threat to population health today. On January 31, 2022, the Banting Research Foundation hosted an interactive virtual open forum on the health challenges related to climate change moderated by Ivan Semeniuk, Science Reporter of The Globe & Mail. Our inspiring panelists included:

- **John Hepburn**  
  CEO, Mitacs
- **Stephen Scherer**  
  Chief of Research, The Hospital for Sick Children
- **Nomazulu Dlamini (2018 Awardee)**  
  Director, Children’s Stroke Program, The Hospital for Sick Children
- **Kate Weinberger (2020 Awardee)**  
  Assistant Professor, School of Population and Public Health, University of British Columbia
- **Gareth Lim (2017 Awardee)**  
  Associate Professor, Canada Research Chair in Adipocyte Development, Department of Medicine, Université de Montréal
- **Jeremy Hirota (2015 Awardee)**  
  Assistant Professor, Department of Medicine, Division of Respirology, Faculty of Health Sciences

The thoughtful conversation highlighted the diversity of health and biomedical research and its impact. Participants learned how:
- Climate change and health are related, including how the Canadian research landscape will be impacted by climate change.
- Specific research programs are evolving focused on climate change.
- Types of supports scientists need to effectively contribute to solutions related to the environmental effects of climate.
- We can effectively equip our next generation of science talent for the fight against climate change and,
- How industry, academia and government can work together to co-design solutions.

Participants had the opportunity to engage in fireside chats with 21 of our outstanding young investigators about their cutting-edge research. Recap of this exciting and informative event is available in our Videos & Media - Banting Research Foundation library.
Now is your chance to help fund biomedical investigation into the health impacts of climate change!

Please consider establishing a named Discovery Award in the amount of $30,000 to help support a new climate change researcher focused on health impacts.

Or if you wish, your gift of any amount can be directed into a Climate Change Discovery Fund to help support young scientists with their work.

Please contact Maurine Kwok to learn more.

Maurine Kwok, Executive Director
ed@bantingresearchfoundation.ca
416 595 9048

Kate Weinberger, PhD 2020 Discovery Awardee

Heat Waves and Child Health in a Warming World

“Not just coronavirus — heat also poses a threat to public health....”

Dr. Kate Weinberger is an environmental epidemiologist with an interdisciplinary background in climate science and environmental health.

Her research focuses on the links between climate change and human health, especially changes in extreme weather events and aeroallergens.
A new health challenge partnership

Mitacs and the Banting Research Foundation will address health disparity in Canada and support postdoctoral research scholars engaged in studies focused on reducing the health risks and inequities caused by climate change.

The new Mitacs-Banting Discovery Postdoctoral Fellowship will:

- Help Canada lead the world in understanding the links between health, equity, and the impacts of climate change. Encourage young scientists to think broadly beyond their scope of expertise and equip them to be future research leaders.
- Offer research training and the development of transferrable skills to support innovation and long-term employability. Share recipient time between academic institutions and eligible partner organizations.
- Support research to examine health outcomes and inequalities among marginalized and underrepresented communities. Increase the quality of internationally competitive, leading-edge research in areas critical to the health, economic, and social well-being of Canadians.

“We are deeply grateful for this opportunity to once again partner with Mitacs. The new Mitacs-Banting Discovery Postdoctoral Fellowship recipients have the exciting potential to increase our understanding of the health risks of climate change.

Through the big bold ideas of our diverse young scientists, we are confident that they can provide fresh insights and help alleviate urgent health challenges through discovery research.”

Dr. Catharine Whiteside
Board Chair, Banting Research Foundation

“When academia and industry work together, we are equipping ourselves and future generations to better address the impacts of climate change like health risks and inequalities.

The Mitacs-Banting fellowship will help develop the cross-cutting solutions we need to ensure no Canadian is left behind as we build a healthier and more sustainable future for all.”

The Rt. Hon. François-Philippe Champagne
Minister of Innovation, Science, & Industry

“The impacts of the climate crisis have become increasingly evident in recent years.

Among these, we see the direct health risks and inequities due to climate change in Canada and across the globe.

This new partnership is an investment in the research needed to mitigate those impacts.”

John Hepburn
CEO, Mitacs
The 2022 Discovery Award Cohort

Banting Discovery Award – Jarislowsky Fellowship

Luka Milosevic, PhD
Scientist, Clinical and Computational Neuroscience, Krembil Research Institute, University Health Network; Assistant Professor, Institute of Biomedical Engineering, University of Toronto

Project: Physiologically-informed and data-driven methods for advancing neuromodulation therapies in dystonia

Banting Discovery Award – Jarislowsky Fellowship

Edward Ian Patterson, PhD
Assistant Professor
Department of Biological Sciences, Faculty of Mathematics and Science, Brock University

Project: Exploiting insect-specific viruses to prevent transmission of arthropod-borne viruses

Banting Discovery Award

Silvia Pozzi, PhD
Assistant Professor, Department of Psychiatry and Neuroscience, Faculty of Medicine, Université Laval

Project: Unraveling the role of PPIA/EMMPRIN pathway in the communication between Schwann cells and motor neurons in ALS

Banting-Mitacs Discovery Award

Kimberly Dunham-Snary, PhD
Assistant Professor, Department of Medicine, Faculty of Health Sciences, Queen’s University

Project: Mitochondrial-metabolomic fingerprinting in cardiometabolic disease

Banting Discovery Award

Amy Huei-Yi Lee, PhD
Assistant Professor, Department of Molecular Biology & Biochemistry (MBB), Faculty of Science, Simon Fraser University

Project: Integrated omics and functional analyses to expand the repertoire of surveillance and drug targets in Pseudomonas aeruginosa

Banting-Dystonia Medical Research Discovery Award

Mihai Duduta, PhD
Assistant Professor, Department of Mechanical Engineering, Faculty of Applied Science & Engineering, University of Toronto

Project: Smart micro-catheters based on electro-mechanical artificial muscles

U of T 100th Anniversary Discovery of Insulin Banting Award

Kimberly Dunham-Snary, PhD
Assistant Professor, Department of Medicine, Faculty of Health Sciences, Queen’s University

Project: Mitochondrial-metabolomic fingerprinting in cardiometabolic disease

Banting-Mitacs Discovery Award

Luka Milosevic, PhD
Scientist, Clinical and Computational Neuroscience, Krembil Research Institute, University Health Network; Assistant Professor, Institute of Biomedical Engineering, University of Toronto

Project: Physiologically-informed and data-driven methods for advancing neuromodulation therapies in dystonia
2022 Discovery Awards Celebration

On the afternoon of July 8th, 2022, we celebrated the 2022 award recipients, new Board members and thanked our donors, volunteers and honored our director emeritus, Dr. Fred Lowy.

The Foundation recognized the long and outstanding contributions and deep commitment of Dr. Lowy, who was completing his final term.

This in-person event included presentations from three of our recent Awardees about their innovative work and successful launch of their research careers. We also had the opportunity to gratefully thank our Board members and to welcome new members including Alain Beaudet, Andrea Donlan, Andre Morriseau and Sheelagh Whittaker.

Another amazing volunteer Dr. Pat Brubaker who served for many years as Scientific Officer on our Grants Review Panel and will be completing her final term this coming year was thanked for her incredible service. Our volunteer Grants Review Panel Chair, Dr. Cindi Morshead was thanked for her leadership. Dr. Anthony Gramolini, a Panel member for several years has graciously agreed to serve as our next Chair.

Finally, we recognized the outstanding contributions of our most dedicated Executive Director, Maurine Kwok, without whom the Foundation would not be building momentum and impact.
Left to right: Bill Hewitt, Retired Board Member, Nona MacDonald Heaslip, Honourary Patron, Don Guloien, Board Member.

Hugh Furneaux, volunteer.

Left to right: Dr. Mahavir Agarwal, Panel Reviewer, Dr. Ian Patterson, 2022 Discovery Awardee, Sheelagh Whittaker, Board Member, Paulette Moser.

Left to right: Charles Best Foundation Board Members: Terrence Donnelly and Dr. Peter Lewis.
Centre: Prof. Molly Verrier, Board Member, Kimberly Dunham Snary, 2022 Banting-Mitacs Discovery Awardee. Back L: Luka Milosevic, 2022 Banting-Dystonia Awardee, Archana Castelino, National Director, Dystonia Foundation

Speaker: Dr. Mihai Duduta, U of T 100th Anniversary Discovery of Insulin Banting Awardee

Dr. Sagi Abelson, 2021 Discovery Awardee, left, and Stanley Ng.

Speaker: Dr. Daiva Nielsen, 2019 Discovery Awardee
Select Discovery Award
Research Highlights

What intrigued or inspired you to choose this specific research question?

The biology and chemistry of sugars has always fascinated me. When I realized we could apply the tools we have been developing to study sugars to stem cells and regenerative medicine, I was inspired to explore this exciting new area.

How would you describe your work to a non-scientist?

Every cell in your body is surrounded by a sugar coating. New techniques in chemistry and biochemistry study these sugars and:

- How they are used to direct cells to specific areas of the body,
- How they are used by the immune system, and
- How pathogens like viruses use sugars to infect us.

One superpower I wish I had in the research world?

To clone my amazing students who drive all the exciting research areas!

Your most important scientific finding?

Proof-of-concept that we could apply our glyco-engineering tools to understand the biological relevance of sugars more efficiently. We have been able to apply our techniques to look at how sugars are involved in different diseases like cancer and virus infections, and better understand this very important class of biological molecule that has been very difficult to study.

How is your area of scientific discovery important for Canadians?

Carbohydrates are crucial for human health and are involved in almost every disease.
Understanding how sugars interact with other biomolecules and how they are functioning in both healthy and diseased states is key to solving many health issues.

**How has Banting Research Foundation helped you in your journey of scientific discovery? Anything you would like to say to our supporters to encourage them to give?**

This was one of the first grants I obtained as a new researcher. I could support graduate students wanting to learn about this research area and it was important for generating preliminary data to apply our techniques to expand into multiple new areas. I am incredibly grateful for this support. It was crucial to securing additional funding and to advancing our research at such a critical stage of my career.

*Left to right: Sara Fraser, Alex Golds, Daniel Whalen, Chantelle Capicciotti, Jonathan Babulic, Joshua Kofsky, Youjin Kim, Marie Boddington, Fabiola De Leon Gonzalez, Pascal Vogt.*
Qu’est-ce qui vous a intrigué -ou inspiré- dans le choix de votre sujet de recherche?

Ce qui m'a intrigué dans la recherche que je fais aujourd'hui c'est le fait qu'un organe jeune comme l'œil embryonnaire peut montrer des signes de vieillissement prématuré qui peut être à la fois bénéfique pour la régénération tissulaire mais détrimental dans le cas de pathologie oculaire comme les vitréorétinopathie.

Comment décririez-vous votre travail de recherche à un auditoire non-scientifique?

L’œil embryonnaire est nourri et oxygéné par des vaisseaux fœtaux transitoires appelés hyaloïdes, qui régressent après la naissance pour être remplacés par des vaisseaux sanguins rétiniens permanents. Lorsque ce processus de régression hyaloïde fait défaut, on observe des maladies caractérisées par un développement rétinien anormal avec une cécité congénitale qui peut causer la perte de vision. Les rétinopathies rares causées par la persistance des vaisseaux hyaloïdes à la naissance se caractérisent par un spectre de modifications vasculaires de la rétine qui progressent au cours de l'enfance ou de l'adolescence pour entraîner divers degrés de déficience visuelle.

Ces maladies sont associées à un grave défaut de la vascularisation rétinienne, il est donc impératif de comprendre le développement vasculaire de l'œil très tôt dans le développement embryonnaire.

Le but ultime de ce programme est d'identifier les cellules embryonnaires qui forment les vaisseaux sanguins de la rétine, ainsi que les molécules qui dirigent leur prolifération, leur migration et leur différenciation. Ces informations nous aideront à mieux comprendre et traiter les maladies oculaires rares mais aussi communes affectant la vue des enfants d'âges différents. J'ai récemment découvert un nouveau mécanisme de sénescence prématurée (vieillissement prématuré) des cellules rétiniennes dans notre modèle murin (rétinopathie induite par l'oxygène) mimant la rétinopathie du prématuré chez l'homme.

Actuellement, mes collaborateurs et moi-même explorons une voie thérapeutique très prometteuse pour traiter cette rétinopathie rare. Notre objectif est d'inverser le processus de vieillissement prématuré affectant la rétine dans la rétinopathie du prématuré et d'autres rétinopathies rares. Les stratégies de traitement actuelles comprennent la photocoagulation au laser ou l'ablation chirurgicale du corps vitré (vitrectomie précoce). Certes, ces interventions permettent une amélioration de la vision en stoppant la progression de la maladie mais la maladie persiste d' où...
l’urgence et la nécessité de développer de nouvelles stratégies thérapeutiques. La découverte de nouveaux marqueurs moléculaires pour ces maladies rares aidera non seulement le diagnostic correct mais aussi le développement de thérapies efficaces améliorant la vue de ces patients.

Si j’avais un superpouvoir dans le domaine de la recherche?

Je l’utiliserais pour trouver la cible thérapeutique qui va servir à améliorer la vie principalement des patients atteints de rétinopathies vasculaires et leur familles.

Quelle a été votre contribution scientifique la plus importante?

En 2016 quand j’ai fait le marquage de la rétine d’une jeune souris avec un marqueur de cellules sénescentes (vieillissantes) et tout le centre de la rétine ischémique pathologique est devenu tout bleu témoignant de la senescence cellulaire. En fait cette découverte a été publiée dans le journal Science transnational médecine en 2016. Cette étude était à la base de tout un champ d’étude qui a permis de cibler la senescence prématurée au niveau des pathologie oculaire avec des drogues nommées sénolytiques. Ces dernières font l’objet des essais cliniques depuis 2019 et là les résultats de la deuxième phase clinique viennent d’être annoncés et sont très encourageants pour passer à la prochaine étape.

En quoi votre domaine de recherche est-il important pour les Canadiens?

En 2050, plus de 61 millions de personnes souffriront de cécité. Actuellement, plus de 596 millions de personnes dans le monde souffrent de déficience visuelle, dont 43 millions de personnes aveugles. La grande hétérogénité clinique et génétique des maladies oculaires, avec leur prévalence mondiale remarquable, est toujours intéressante pour les chercheurs généticiens, comme moi, qui peut comprendre comment une mauvaise vision peut avoir des effets négatifs sur la qualité de vie, l’éducation et l’indépendance des gens.

Bien que l’association de nombreux gènes avec les troubles oculaires ait été démontrée, le développement de meilleurs diagnostics et des stratégies thérapeutiques pour des recherches plus approfondies sont nécessaires pour identifier les molécules clés et les voies impliquées dans l’aprogession des déficiences visuelles.

Current treatment strategies include laser photocoagulation or surgical removal of the vitreous (early vitrectomy). Admittedly, these interventions allow an improvement of the vision by stopping the progress of the disease, but the disease persists hence the urgency and the need to develop new therapeutic strategies.

The discovery of new molecular markers for these rare diseases will help not only the correct diagnosis but also the development of effective therapies improving the eyesight of these patients. These objectives are in perfect harmony with the primary mission of our research center on orphan diseases.

Comment la Fondation Banting vous a-t-elle aidée dans la poursuite de vos objectifs scientifiques? Que diriez-vous à nos donateurs pour les encourager à contribuer davantage?

Le Banting est parmi les premières subventions que j’ai eues comme Early Career Researcher et ça m’a beaucoup aidé pour démarrer mon programme de recherche et a servi comme effet levier pour décrocher ma chaire de recherche du canada en senescence et développement vasculaire entre autres.

UN GRAND MERCI À LA FONDATION BANTING!
What intrigued or inspired you to choose this specific research question?

As an undergrad, I fell in love with biomechanics research, where technology comes together with physics and biology to track how the body moves and reacts to forces.

How would you describe your work to a non-scientist?

Millions of Canadians are diagnosed with osteoarthritis, a complex disease that often puts older adults at a loss for how they can best improve their function and reduce their pain. I want to integrate biomechanical testing to support clinicians in identifying patient-specific models that can optimize treatment plans and improve quality of life.

One superpower I wish I had in the research world?

Superspeed! I’m an early career researcher, advancing towards exciting new scientific discoveries. I also teach, and I’m also a husband and father to three young boys – it is all a very delicate balancing act.

Superspeed would allow me to accomplish more. Not to mention, having this superpower in a biomechanics lab could drive some very interesting research on the mechanics and physiology behind my own powers.

Your most important scientific finding?

I developed predictive models for treatment plans in older adults with knee osteoarthritis.

These models involved data on people’s movement patterns, combined with their clinical status. Further, we were able to translate these to a variety of clinics across the country that had access to our lab’s motion capture technology.

Patients came in for their final session to say that they hadn’t felt this good in years and they could do activities they thought they would never be able to do again. I was drawn to science for the behind-the-scenes discoveries – but seeing the work translated to those in need is what really makes my job special.

How is your area of scientific discovery important for Canadians?

Unfortunately, like many countries in the
world, our health care system poorly manages older adults with musculoskeletal pain and disorders.

Patients are often made to feel that this is a normal part of aging and are sent home to manage pain on their own, while awaiting a potential surgical intervention that may never come or may never improve their situation.

Developing more patient-specific recommendations of treatment using biomechanical technologies – can drastically improve how these patients can manage their osteoarthritis and improve their quality of life as they age.

**Anything you would like to say to our supporters to encourage them to give?**

The Discovery Award has been a massive support in the journey of scientific discovery. It allowed me to attract some impressive talent to my lab and ask larger, more impactful questions. Further, the network and scholarly support offered by the Foundation was a true blessing throughout the COVID-19 pandemic.

Therefore, I offer a heartfelt thank you to all the supporters. Not only for the monetary support of our work, but for the recognition of our efforts and the support system that you have made possible.

I cannot thank you enough for this opportunity and this amazing network you have so graciously supported.

*Left to right: Ese Orogun, Dylan Kobsar, Fatima Gafoor, Matthew Ruder, Chilly Gavrilov, Josh Keogh, Jenny Wu, Anil Palanisamy.*
What intrigued or inspired you to choose this specific research question?

Curiosity and a positive perspective about the future management of cancer drove me to become a researcher. With a growing aging population and the higher rates of cancer incidence in this group, there is a critical need to understand and focus on evidence-based approaches to identify new cancer vulnerabilities and markers for early detection.

How would you describe your work to a non-scientist?

We aim to discover the advantages that some cells possess, and study those biological markers in their association with cancer progression and other adverse health outcomes related to the ageing process.

We generate and analyze different types of data and develop new computational tools. Our goal is to facilitate personalized cancer treatment and prevention.

Among the different exciting data that we study is cancer genomics, which can tell us what mutations drive the initiation of cancers, and epigenetics that affects how genes are read by cancer cells.

With the generous support of the Banting Research Foundation, we developed a pan-cancer, machine learning-based tool that can infer the identities of single cells in tumour microenvironments. We aim to continue leveraging this tool to learn what genes different cell population express, and how cancer cells manipulate their environment to interact with non-cancer cells to their advantage.

One superpower I wish I had in the research world?

To become tiny! To reduce my size and teleport myself into cells to see how things really work.

I guess that's two superpowers, though.

What is your most important scientific finding? Your most surprising finding?

We discovered that harmful mutations could be detected in the blood of asymptomatic individuals, years before being diagnosed with acute myeloid leukemia.

I remember getting the raw sequencing information of the first samples. I was so anxious to see if there was any signal, so without waiting for the analysis to be complete, I skimmed through the unprocessed data looking only for the most common leukemia mutations. I jumped from my chair when I found them!
Later, we provided proof for the feasibility of early detection of acute myeloid leukemia.

**How is your area of scientific discovery important for Canadians?**

We now know that clonal hematopoiesis encompasses a whole spectrum of conditions. These include the development of blood cancers and cardiovascular diseases as well as other adverse outcomes following cancer treatments and overall mortality. As clonality of the blood system is an ageing-related phenomenon, it affects us all. Early detection and intervention of clonal hematopoiesis can translate to healthier ageing.

**Anything you would like to say to our supporters to encourage them to give?**

As an early career investigator, the Discovery Award is a tremendous help for investigators to increase their scientific output, support their teams, develop early-stage research programs, and be competitive for future funding competitions.
Research Focus: Addressing Informative Presence Bias in Analyses of Electronic Health Records

Discovery award funding supported two student trainees via Graduate Research Studentships between July 2021 and August 2022.

The first trainee developed better longitudinal data-generating mechanisms to mimic informative presence bias and conducted simulation studies investigating the patterns of bias caused by different scenarios. This work was interrupted due to unforeseen medical reasons.

The second trainee reviewed existing correction methods for misclassification bias and is extending these methods to the case of informative presence bias. The trainee is developing several strategies, including a novel model-based extension to SIMEX, and a multiple imputation approach, which have performed well in simulations.

In addition, this trainee has been accepted into the PhD in biostatistics program at Queen’s University.

I have received access to electronic health record data from Maccabee Health Services (Israel). In collaboration with Dr. Ran Rotem (Harvard), our team plans to apply correction methods to these real data in the months to come.
# Thankful and Flourishing

## How we use our funds

<table>
<thead>
<tr>
<th>BALANCE SHEET</th>
<th>CONDENSED STATEMENT OF REVENUE AND EXPENSES AND CHANGES IN FUND BALANCES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>As at June 30</strong></td>
<td><strong>Year ended June 30</strong></td>
</tr>
<tr>
<td><strong>2022</strong></td>
<td><strong>2021</strong></td>
</tr>
<tr>
<td><strong>$</strong></td>
<td><strong>$</strong></td>
</tr>
<tr>
<td><strong>Assets</strong></td>
<td><strong>REVENUE</strong></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>89,044</td>
</tr>
<tr>
<td>HST recoverables</td>
<td>10,491</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>5,152,477</td>
</tr>
<tr>
<td>Artwork</td>
<td>60,000</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>5,312,012</td>
</tr>
<tr>
<td><strong>Liabilities and Fund Balances</strong></td>
<td><strong>Excess (deficiency) of revenue over expenses for the year</strong></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td><strong>2022</strong></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>111,935</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>111,935</td>
</tr>
<tr>
<td><strong>Fund balances</strong></td>
<td><strong>Excess (deficiency) of revenue over expenses for the year</strong></td>
</tr>
<tr>
<td>General Fund</td>
<td>874,030</td>
</tr>
<tr>
<td>Restricted Fund Endowment Fund</td>
<td>174,796</td>
</tr>
<tr>
<td>Endowment Fund</td>
<td>4,151,251</td>
</tr>
<tr>
<td><strong>Total Fund Balances</strong></td>
<td>5,200,077</td>
</tr>
<tr>
<td>5,312,012</td>
<td>6,008,588</td>
</tr>
</tbody>
</table>

The Condensed Statement is an excerpt of the audited financial statements by Baker Tilly WM LLP, Chartered Professional Accounts. Detailed FY2022 Financial Statements are available upon request.
2022 Discovery Award
Grant Panel Reviewers

Dr. Cindi Morshead
Panel Co-Chair
Professor & Chair, Division of Anatomy and Department of Surgery
University of Toronto

Dr. Susan George Bahl, CM
Panel Co-Chair
1988 Discovery Awardee
Professor, Department of Medicine and Pharmacology & Toxicology
University of Toronto

Dr. Patricia Brubaker
Scientific Officer
Professor, Departments of Physiology and Medicine,
University of Toronto

Dr. Ali Abdul-Sater
2018 Discovery Awardee
Assistant Professor,
Department of Kinesiology & Health Science
York University

Dr. Mahavir Agarwal
Assistant Professor,
Department of Psychiatry, University of Toronto
Medical Head, Clinical Research
Schizophrenia Division, Centre for Addiction & Mental Health

Dr. Brian Ballios
Assistant Professor, Department of Ophthalmology & Vision Sciences, University of Toronto

Dr. Anthony Gramolini
Professor, Department of Physiology
University of Toronto

Dr. Walid A. Houry
Professor, Departments of Biochemistry and Chemistry
University of Toronto

Dr. Salim Timo Islam
2018 Discovery Awardee
Associate Professor, Microbiology & Biotechnology,
Armand-Frappier Santé Biotechnologie Research Centre, IRNS

Dr. Dehan Kong
Assistant Professor, Department of Statistical Sciences
University of Toronto

Dr. Lindi Li
Professor & Harold Robinson-Arthritis Society Chair in Arthritic Diseases
CRC Chair in Patient-oriented Knowledge Translation
Director, Arthritis, Joint Health & Knowledge Translation Research Program,
Department of Physical Therapy
University of British Columbia
Dr. Daniel Moore  
Assistant Professor, Faculty of Kinesiology and Physical Education  
University of Toronto

Dr. Aaron W Reinke  
Assistant Professor, Department of Molecular Genetics  
University of Toronto

Dr. Janice Robertson  
Professor, Tanz Centre for Research in Neurodegenerative Disease  
University of Toronto

Dr. Jonathan Rocheleau  
Associate Professor, Institute of Biomaterials & Biomedical Engineering  
University of Toronto

Dr. Emily Seto  
Assistant Professor, Institute of Health Policy, Management and Evaluation  
University of Toronto

Dr. Lei Sun  
Professor, Department of Statistics and Biostatics  
University of Toronto
A special thank you

We are very grateful to Dr. Fred Lowy, who retired from our Board on June 30, 2022, for his long and extraordinary contributions to the Foundation. Most recently, the relationship that Dr. Lowy has fostered with The Jarislowsky Foundation enabled us to grow our Discovery Award program funding for the period 2020 to 2022.

We can’t do it without the help of our volunteers, friends, partners, and donors, who contributed to our mission. We appreciate your deepest commitment in fiscal 2022.

Above $10,000

- Dystonia Medical Research Foundation
- Mitacs
- The Jarislowsky Foundation
- The William and Nona MacDonald Heaslip Foundation

Up to $10,000

- The Henry White Kinnear Foundation
- Donald A. Guloien and Irene A. Boychuk

Up to $5,000

- Anonymous
- John Burns
- University of Toronto McLaughlin Centre
- Catharine Whiteside

Up to $500

- Toni Allen
- John Floras
- Shanon Grauer
- Gerry Lokash
- Andre Morriseau
- J. Keith Stokes
- Molly Verrier

Many thanks to the University of Toronto Temerty Faculty of Medicine for their continued support, providing us with office space.
The Banting Research Foundation at 100

The Banting Research Foundation has been a talent spotting beacon since 1925.

Named after Dr. Frederick Banting, we support early career researchers who work on the leading edge of biomedical, and health & climate change challenges. Celebrating our 100th anniversary in 2024, we are inspired by all our extraordinary Discovery Awardees.

Please continue to support us!
The Banting Research Foundation, the oldest medical discovery foundation in Canada was founded in 1925 and is a federally incorporated non-profit organization.

Join our Campaign and help us celebrate our 100 years of Discovery in early 2024.

Charitable registration number: 108072927 RR 0001